We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Microsoft, Bank of America, Roche and GSI Technology
Read MoreHide Full Article
For Immediate Release
Chicago, IL – May 6, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Microsoft Corp. (MSFT - Free Report) , Bank of America Corp. (BAC - Free Report) , Roche Holding AG (RHHBY - Free Report) and GSI Technology, Inc. (GSIT - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Analyst Reports for Microsoft, Bank of America and Roche
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corp., Bank of America Corp. and Roche Holding AG, as well as a micro-cap stock GSI Technology, Inc. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
Shares of Microsoft have declined -3.8% over the past year against the Zacks Computer - Software industry’s decline of -6.5%. The company’s customer concentration risk remains tied to large OpenAI-related Azure commitments. Microsoft confronts intense competition from AWS and Google Cloud and escalating regulatory scrutiny. Capacity constraints persisting through fiscal year-end limit revenue potential despite unprecedented spending.
Nevertheless, Microsoft capitalizes on AI business momentum and Copilot adoption alongside accelerating Azure cloud infrastructure expansion. Strong Microsoft 365 Commercial cloud demand has been propelling Productivity and Business Processes revenue growth. ARPU is increasing through E5 and M365 Copilot uptake across key segments.
Strategic execution through expanding scale and enterprise customer growth is driving non-AI services. Azure growth guidance projects Q4 growth of 39-40% at cc, suggesting demand saturation, with customer demand exceeding available capacity.
Bank of America’s shares have gained +30.7% over the past year against the Zacks Financial - Investment Bank industry’s gain of +35.4%. The company’s first-quarter 2026 results were aided by net interest income (NII) growth and strength in trading and investment banking (IB) businesses. Despite lower average rates, NII growth is expected to continue supported by steady loan growth and lower funding costs.
Bank of America’s expansion strategy by opening financial branches in new and existing markets will boost the top line. Along with this, investments in digital capabilities will enhance client engagement and cross-selling opportunities, likely driving fee income.
Yet, the company’s shares have underperformed the industry in the past six months. Elevated expenses due to investments in technology and franchise expansion will likely hurt profits. The volatile nature of the capital markets business makes growth in trading revenues uncertain. Weak asset quality is another concern.
Shares of Roche have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+26% vs. +21.2%). The company performance in the first quarter was weighed down by unfavorable foreign-exchange movements, as weakness in the U.S. dollar adversely impacted international sales.
Nonetheless, the company’s underlying operational performance remained solid. Strong growth from key products helped offset declining revenues from legacy drugs. The stellar performances of multiple sclerosis drug Ocrevus and ophthalmology drug Vabysmo continue to drive momentum for Roche.
Growth in hemophilia treatment Hemlibra and breast cancer drug Phesgo also boosted the top line. Roche is looking to diversify its portfolio through acquisitions and collaborations in the wake of declining sales from legacy drugs (Avastin, Herceptin, MabThera and Actemra) due to competition from biosimilars. However, pipeline and regulatory setbacks weigh on the stock.
GSI Technology’s shares have gained +129.7% over the past year against the Zacks Computer- Storage Devices industry’s gain of +519.5%. This microcap company with a market capitalization of $282.61 million is driven by its strengthened capital base, strategic edge AI positioning, and government partnerships. With $70.7 million in cash and no debt, GSI is well-funded to scale R&D and product rollout, especially for its Gemini-II processor, which demonstrated superior power efficiency in edge AI benchmarks.
GSI Technology is targeting high-growth sectors like drones and mobile robotics with AI chips optimized for low-latency and low-power environments. Government contracts in defense and aerospace validate its technology, while the legacy SRAM business continues to generate stable cash flows.
However, rising R&D costs, widening operating losses and reliance on early-stage government projects present notable execution challenges. A structural decline in legacy segments poses transitional risk. Valuation appears stretched relative to peers.
Free: Instant Access to Zacks' Market-Crushing Strategies
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
The Zacks Analyst Blog Highlights Microsoft, Bank of America, Roche and GSI Technology
For Immediate Release
Chicago, IL – May 6, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Microsoft Corp. (MSFT - Free Report) , Bank of America Corp. (BAC - Free Report) , Roche Holding AG (RHHBY - Free Report) and GSI Technology, Inc. (GSIT - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Analyst Reports for Microsoft, Bank of America and Roche
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corp., Bank of America Corp. and Roche Holding AG, as well as a micro-cap stock GSI Technology, Inc. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Pre-Markets Bounce Back from Monday's Selloff
Today's Featured Research Reports
Shares of Microsoft have declined -3.8% over the past year against the Zacks Computer - Software industry’s decline of -6.5%. The company’s customer concentration risk remains tied to large OpenAI-related Azure commitments. Microsoft confronts intense competition from AWS and Google Cloud and escalating regulatory scrutiny. Capacity constraints persisting through fiscal year-end limit revenue potential despite unprecedented spending.
Nevertheless, Microsoft capitalizes on AI business momentum and Copilot adoption alongside accelerating Azure cloud infrastructure expansion. Strong Microsoft 365 Commercial cloud demand has been propelling Productivity and Business Processes revenue growth. ARPU is increasing through E5 and M365 Copilot uptake across key segments.
Strategic execution through expanding scale and enterprise customer growth is driving non-AI services. Azure growth guidance projects Q4 growth of 39-40% at cc, suggesting demand saturation, with customer demand exceeding available capacity.
(You can read the full research report on Microsoft here >>>)
Bank of America’s shares have gained +30.7% over the past year against the Zacks Financial - Investment Bank industry’s gain of +35.4%. The company’s first-quarter 2026 results were aided by net interest income (NII) growth and strength in trading and investment banking (IB) businesses. Despite lower average rates, NII growth is expected to continue supported by steady loan growth and lower funding costs.
Bank of America’s expansion strategy by opening financial branches in new and existing markets will boost the top line. Along with this, investments in digital capabilities will enhance client engagement and cross-selling opportunities, likely driving fee income.
Yet, the company’s shares have underperformed the industry in the past six months. Elevated expenses due to investments in technology and franchise expansion will likely hurt profits. The volatile nature of the capital markets business makes growth in trading revenues uncertain. Weak asset quality is another concern.
(You can read the full research report on Bank of America here >>>)
Shares of Roche have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+26% vs. +21.2%). The company performance in the first quarter was weighed down by unfavorable foreign-exchange movements, as weakness in the U.S. dollar adversely impacted international sales.
Nonetheless, the company’s underlying operational performance remained solid. Strong growth from key products helped offset declining revenues from legacy drugs. The stellar performances of multiple sclerosis drug Ocrevus and ophthalmology drug Vabysmo continue to drive momentum for Roche.
Growth in hemophilia treatment Hemlibra and breast cancer drug Phesgo also boosted the top line. Roche is looking to diversify its portfolio through acquisitions and collaborations in the wake of declining sales from legacy drugs (Avastin, Herceptin, MabThera and Actemra) due to competition from biosimilars. However, pipeline and regulatory setbacks weigh on the stock.
(You can read the full research report on Roche here >>>)
GSI Technology’s shares have gained +129.7% over the past year against the Zacks Computer- Storage Devices industry’s gain of +519.5%. This microcap company with a market capitalization of $282.61 million is driven by its strengthened capital base, strategic edge AI positioning, and government partnerships. With $70.7 million in cash and no debt, GSI is well-funded to scale R&D and product rollout, especially for its Gemini-II processor, which demonstrated superior power efficiency in edge AI benchmarks.
GSI Technology is targeting high-growth sectors like drones and mobile robotics with AI chips optimized for low-latency and low-power environments. Government contracts in defense and aerospace validate its technology, while the legacy SRAM business continues to generate stable cash flows.
However, rising R&D costs, widening operating losses and reliance on early-stage government projects present notable execution challenges. A structural decline in legacy segments poses transitional risk. Valuation appears stretched relative to peers.
(You can read the full research report on GSI Technology here >>>)
Free: Instant Access to Zacks' Market-Crushing Strategies
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached.
Get all the details here >>
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.